Redhill Biopharma Ltd. (RDHL) Social Stream
RedHill Biopharma Ltd (RDHL) Price Targets From Analysts
Use the tables below to see what analysts covering RedHill Biopharma Ltd think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 107 days, RDHL's average price target has gone down $1.17.
Over the past 129 days, RDHL's average upside potential has been 557.5%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
RDHL Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
RDHL's average broker recommendation rating worsened by 0.2 over the prior 18 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, RedHill Biopharma Ltd's upside potential (average analyst target price relative to current price) is higher than 682.01% of them.
- RedHill Biopharma Ltd's variance in analysts' estimates is lower than -577.37% of all US stocks.
- RedHill Biopharma Ltd's number of analysts covering the stock is greater than 574.37% of stocks in the small market cap category.
- In terms of how RedHill Biopharma Ltd fares relative to Healthcare stocks, note that its average analyst price target is greater than 223.41% of that group.
What is the outlook for RDHL? Use POWR Ratings for clearer insight into price direction.